Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 1/20 | 0.50 |
| ▸ | DRD2 | P14416 | 2/20 | 0.46 |
| ▸ | DRD3 | P35462 | 1/20 | 0.46 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.46 |
| ▸ | BAD | Q92934 | 1/20 | 0.46 |
| ▸ | ESR1 | P03372 | 1/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.44 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.44 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.44 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.44 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP4B1 | P13584 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12674518 | 1.00 | ADRA2A (0.50) | ADRA2ADRD2DRD3BCL2L1BAD | |
| Hydrochloric Acid SCHEMBL13269175 | 0.98 | ADRA2A (0.49) | ADRA2ADRD2DRD3BCL2L1BAD | |
| Bromide SCHEMBL10357248 | 0.98 | ADRA2A (0.49) | ADRA2ADRD2DRD3BCL2L1BAD | |
| SCHEMBL4202381 | 0.89 | DRD2 (0.53) | DRD2DRD3ESR1ESR2CYP1A1 | |
| SCHEMBL13573563 | 0.89 | DRD2 (0.53) | DRD2DRD3ESR1ESR2CYP1A1 | |
| SCHEMBL8411065 | 0.83 | ADRA2A (0.51) | ADRA2A | |
| SCHEMBL454127 | 0.79 | ADRA2A (0.51) | ADRA2ADRD2BCL2L1BADESR1 | |
| SCHEMBL3585626 | 0.79 | ADRA2A (0.43) | ADRA2ATAS1R3TAS1R1TAS1R2 | |
| SCHEMBL1150666 | 0.79 | ADRA2A (0.43) | ADRA2ATAS1R3TAS1R1TAS1R2 | |
| SCHEMBL7327615 | 0.79 | ADRA2A (0.51) | ADRA2ADRD2CYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103906514-A | Compositions and methods for treating metabolic disorders | BIOMED VALLEY DISCOVERIES INC | 2014-07-02 | — | — | CN | claimed |
| CN-1929829-B | (S) -2-N-propylamino-5-hydroxytetraline as D3 agonist | SANOL ARZNEI SCHWARZ GMBH | 2010-12-15 | — | — | CN | claimed |
| CN-1929829-A | (S) -2-N-propylamino-5-hydroxytetraline as D3 agonist | SANOL ARZNEI SCHWARZ GMBH (DE) | 2007-03-14 | — | — | CN | claimed |
| EP-0463119-A4 | SUBSTITUTED 2-AMINOTETRALINS | — | 1992-01-22 | — | — | EP | claimed |
| EP-0463119-A1 | use of SUBSTITUTED 2-AMINOTETRALINS for the preparation of a medicament for inducing anorexia or weight loss. | Whitby Research Incorporated (US) | 1992-01-02 | — | — | EP | claimed |
| US-11198685-B2 | Substituted ureas and methods of making and using same | MEBIAS DISCOVERY, INC. (US) | 2021-12-14 | — | — | US | disclosed |
| US-20200308155-A1 | Substituted Ureas and Methods of Making and Using Same | MEBIAS DISCOVERY, INC. | 2020-10-01 | — | — | US | disclosed |
| US-10683283-B2 | Substituted ureas and methods of making and using same | MEBIAS DISCOVERY, INC. (US) | 2020-06-16 | — | — | US | disclosed |
| US-10174033-B2 | N6-substituted adenosine derivatives and N6-substituted adenine derivatives and uses thereof | INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2019-01-08 | — | — | US | disclosed |
| CN-103906514-A | Compositions and methods for treating metabolic disorders | BIOMED VALLEY DISCOVERIES INC | 2014-07-02 | — | — | CN | disclosed |
| CN-101534809-B | Use of substituted 2-amino-1, 2,3, 4-tetrahydronaphthalenes for producing medicaments for the prophylaxis, alleviation and/or treatment of various types of pain | UCB PHARMA GMBH | 2013-03-13 | — | — | CN | disclosed |
| US-20130045942-A1 | N6-SUBSTITUTED ADENOSINE DERIVATIVES AND N6-SUBSTITUTED ADENINE DERIVATIVES AND USES THEREOF | INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2013-02-21 | — | — | US | disclosed |
| CN-1897935-A | Use of rotigotine for treatment or prevention of dopaminergic neurone loss | SANOL ARZNEI SCHWARZ GMBH (DE) | 2007-01-17 | — | — | CN | disclosed |
| EP-0253257-B1 | SUBSTITUTED AMINO-5,6,7,8-TETRAHYDRONAPHTHYL-OXYACETIC ACIDS, METHOD FOR THEIR PREPARATION AND THEIR APPLICATION AS MEDICAMENTS | BAYER AG (DE) | 1990-11-14 | — | — | EP | disclosed |
| US-4921998-A | ANTICOAGULANTS, ANTIISCHEMIC AGENTS, ATHEROSCLEROSIS | BAYER AKTIENGESELLSCHAFT (DE) | 1990-05-01 | — | — | US | disclosed |
| EP-0179667-B1 | N6-SUBSTITUTED ADENOSINES | WARNER-LAMBERT COMPANY (US) | 1989-12-27 | — | — | EP | disclosed |
| US-4868331-A | ANTICOAGULANTS, ANTIATHEROSCLEROTIC, ANTIISCHEMIC | BAYER AKTIENGESELLSCHAFT (DE) | 1989-09-19 | — | — | US | disclosed |
| US-4791103-A | HYPOTENSIVE AGENTS, PSYCHOLOGICAL DISORDERS | WARNER-LAMBERT COMPANY (US) | 1988-12-13 | — | — | US | disclosed |
| EP-0253257-A2 | Substituted amino-5,6,7,8-tetrahydronaphthyl-oxyacetic acids, method for their preparation and their application as medicaments | BAYER AG (DE) | 1988-01-20 | — | — | EP | disclosed |
| EP-0179667-A2 | N6-substituted adenosines | WARNER-LAMBERT COMPANY (US) | 1986-04-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10683283-B2 | Substituted ureas and methods of making and using same | UMPS, METTL3, UTS2R | ADRA2A 3051/4885DRD2 3348/4885DRD3 2618/4885 |
| US-11198685-B2 | Substituted ureas and methods of making and using same | UMPS, METTL3, UTS2R | ADRA2A 3051/4885DRD2 3348/4885DRD3 2618/4885 |
| US-20200308155-A1 | Substituted Ureas and Methods of Making and Using Same | UMPS, METTL3, UTS2R | ADRA2A 3051/4885DRD2 3348/4885DRD3 2618/4885 |
| US-10174033-B2 | N6-substituted adenosine derivatives and N6-substituted adenine derivatives and uses thereof | ADORA2A, ADORA3, ADORA1 | ADRA2A 245/4885DRD2 220/4885DRD3 376/4885 |
| US-20130045942-A1 | N6-SUBSTITUTED ADENOSINE DERIVATIVES AND N6-SUBSTITUTED ADENINE DERIVATIVES AND USES THEREOF | ADORA2A, ADORA3, ADORA1 | ADRA2A 245/4885DRD2 220/4885DRD3 376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.